Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The mandate of this MPN registry is to collect clinical information, including molecular results, from consenting patients with a variety of MPNs at different time points during the course of their disease.
The myeloproliferative neoplasms (MPNs) are a group of rare hematological malignancies in which the bone marrow cells that produce the body's blood cells develop and function abnormally.
Despite the gains that have already been made in understanding and treatment of MPNs there is much that can still be learned. This registry will establish a clinical annotation database would help to better understand this group of diseases and to more effectively assign individual patients to the optimal therapy and so, improve their outcomes. This project will provide new insights on the molecular profiling of patients with MPN. It will be used as future resource for observational studies related to MPN.
The registry involves the collection of clinical information from patients with diagnosis of MPN at different time points during the course of their disease. The clinical data is collected following written informed consent from the Hematologic Malignancy tissue bank (UHN REB 01-0573C).
Data collected includes: a range of clinical measures, disease-associated factors, details of treatment and its results, complications during treatment, molecular and cytogenetic data, symptom assessment and survival outcome (up to 10 years).
Data will be collected prospectively and retrospectively, in both cases after obtaining written informed consent as per the study standard operating procedure (SOP).
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Patients with a diagnosis of MPN | Patients with a myeloproliferative neoplasm (MPN) diagnosis: Atypical chronic myeloid leukemia (aCML), chronic eosinophilic leukemia-not otherwise specified (CEL NOS), chronic myelomonocytic leukemia (CMML), chronic neutrophilic leukemia (CNL), polycythemia vera (PV), essential thrombocythemia (ET), JMML, mastocytosis, MPN unclassifiable, myeloproliferative neoplasm/myelodysplastic syndrome unclassifiable (MPN/MDS unclassifiable), primary myelofibrosis (PMF), post-ET MF, post-PV MF, or (refractory anemia with ringed sideroblasts associated with marked thrombocytosis) RARS-T |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Observational | Other |
|
| Measure | Description | Time Frame |
|---|---|---|
| Survival | Survival of patients with MPN | Annually or at the time of transformation of disease, up to 10 years |
| Measure | Description | Time Frame |
|---|---|---|
| General patient characteristics will be captured from the Hematologic Malignancy tissue bank | Type and phase of MPN, previous cancer history, age, sex | Annually or at the time of transformation of disease, up to 10 years |
| Disease risk score |
Not provided
Inclusion Criteria:
Diagnosis of one of the following myeloproliferative neoplasms (MPNs):
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Patients at Princess Margaret Cancer Centre with an MPN diagnosis who consent to inclusion in this registry.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Vikas Gupta, MD | Contact | 416-946-4521 | 4521 | vikas.gupta@uhn.ca |
| Jaime O. Claudio, PhD | Contact | 416-946-4501 | 2648 | jclaudio@uhnresearch.ca |
| Name | Affiliation | Role |
|---|---|---|
| Vikas Gupta, MD | University Health Network, Toronto | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Princess Margaret Cancer Centre | Recruiting | Toronto | Ontario | M5G 1Z5 | Canada |
De-identified participant data may be shared for REB approved research studies. Only the data necessary to achieve the study's aims will be shared and all data will be de-identified prior to sharing.
Not provided
Continuing
De-identified participant data may only be shared for REB approved research studies.
Not provided
Not provided
Not provided
Not provided
Not provided
Risk stratification (IPSS, DIPSS and DIPSS)
o Details of transformation to accelerated/phase phase disease
| Annually or at the time of transformation of disease, up to 10 years |
| Quality of life - Neoplasm Symptom | MPN-SAF TSS questionnaire | Annually or at the time of transformation of disease, up to 10 years |
| Co-morbidities | HCT-CI | Annually or at the time of transformation of disease, up to 10 years |
| Physical symptoms of MPN | Physical examination: Splenomegaly and hepatomegaly, ascites, EMS, ECOG | Annually or at the time of transformation of disease, up to 10 years |
| MPN treatment type received | Medical therapies received | Annually or at the time of transformation of disease, up to 10 years |
| Transfusion dependence status | Transfusion status | Annually or at the time of transformation of disease, up to 10 years |
| Current Blood Work | CBC, INR, PT, APTT, fibrinogen, creatinine, ALP, ALT, AST, GGT, total bilirubin, LDH, urate, CRP, erythropoietin, hepatitis B and HIV | Annually or at the time of transformation of disease, up to 10 years |
| Identifying MPN driver mutations by using next generation sequencing. | Next generation sequencing gene panel | Annually or at the time of transformation of disease, up to 10 years |
| Bone marrow transplant details (if received) | Details of recipient (CMV status, ABO blood group)
| Annually or at the time of transformation of disease, up to 10 years |
| Bone marrow transplant complications (if received) | Toxicities, engraftment and chimerism, GVHD, significant infections in the first 100 days | Annually or at the time of transformation of disease, up to 10 years |
| Portal hypertension | Presence and details of ascites, GIT bleeding, esophageal & gastric varices, cirrhosis and portal hypertensive gastropathy o Endoscopy results | Annually or at the time of transformation of disease, up to 10 years |
| Pulmonary hypertension | WHO classification, echocardiogram results, CNP, troponin, pulmonary function tests, 6 minute walk test distance, blood gas, treatment, complications | Annually or at the time of transformation of disease, up to 10 years |
| Thrombosis | Details of thrombosis (type, site) o Treatment of thrombosis (type, duration) | Annually or at the time of transformation of disease, up to 10 years |
| Family history of MPN will be obtained from the patient record. | Relative affected (e.g. daughter, uncle, mother), details of MPN (type, phase, treatment received) | Annually or at the time of transformation of disease, up to 10 years |
| Disease progression | Risk stratification (IPSS, DIPSS and DIPSS) | Annually or at the time of transformation of disease, up to 10 years |
| ID | Term |
|---|---|
| D055728 | Primary Myelofibrosis |
| D011087 | Polycythemia Vera |
| D013920 | Thrombocythemia, Essential |
| D008415 | Mastocytosis |
| D054438 | Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative |
| D054429 | Leukemia, Myelomonocytic, Juvenile |
| D017681 | Hypereosinophilic Syndrome |
| D054437 | Myelodysplastic-Myeloproliferative Diseases |
| D009369 | Neoplasms |
| D015477 | Leukemia, Myelomonocytic, Chronic |
| D009196 | Myeloproliferative Disorders |
| D009190 | Myelodysplastic Syndromes |
| D007938 | Leukemia |
| D001855 | Bone Marrow Diseases |
| D006402 | Hematologic Diseases |
| ID | Term |
|---|---|
| D006425 | Hemic and Lymphatic Diseases |
| D019046 | Bone Marrow Neoplasms |
| D019337 | Hematologic Neoplasms |
| D009371 | Neoplasms by Site |
| D001778 | Blood Coagulation Disorders |
| D013922 | Thrombocytosis |
| D001791 | Blood Platelet Disorders |
| D006474 | Hemorrhagic Disorders |
| D009372 | Neoplasms, Connective Tissue |
| D018204 | Neoplasms, Connective and Soft Tissue |
| D009370 | Neoplasms by Histologic Type |
| D000090362 | Mast Cell Activation Disorders |
| D007154 | Immune System Diseases |
| D007951 | Leukemia, Myeloid |
| D002908 | Chronic Disease |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D004802 | Eosinophilia |
| D007960 | Leukocyte Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| D057832 | Watchful Waiting |
| ID | Term |
|---|---|
| D017063 | Outcome Assessment, Health Care |
| D010043 | Outcome and Process Assessment, Health Care |
| D011787 | Quality of Health Care |
| D006298 | Health Services Administration |
Not provided
Not provided